CutPRO® Cut Resistant Clothing Sponsoring Leading Glass Event ‘Glass Focus 2019’
19.11.2019 11:00:00 EET | Business Wire | Press release
British firm CutPRO® is sponsoring this year’s ‘Glass Focus 2019’ event taking place on 21 November in Sheffield, United Kingdom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005029/en/
CutPRO® is a pioneering British brand of high performance cut resistant clothing, providing fully CE certified, EN 388:2016 tested and thoroughly field tested cut protection. (Graphic: Business Wire)
Robert Kaiser, CEO of PPSS Group, the firm behind the CutPRO® brand, also announced it had entered the ‘Health and Safety Action’ category: “We have high hopes to win this prestigious award. Our innovative and pioneering brand of high performance cut resistant clothing somewhat deserves that level of recognition”.
The event is organised by ‘British Glass’, the representative body for the UK industry. Communicating the glass sector’s values and interests, their aim is to secure a thriving and sustainable future.
UK based PPSS Group has been producing cut resistant clothing for the past ten years, its sole purpose being the protection of frontline professionals in sectors where cuts and lacerations are a high risk e.g. homeland security.
In February 2018 the now highly acclaimed CutPRO® brand was launched, again using their very own Cut-Tex® PRO cut resistant fabric. Cut-Tex® PRO has achieved outstanding levels of cut, tear, abrasion and puncture resistance, while being extremely durable, lightweight and rather comfortable.
As a single layer it is offering ANSI/ISEA 2016 Blade Cut Resistance Level A5.
CutPRO®s Senior Product Consultant Eve Ichim operated as a liaison between potential customers and the firm’s production team, gathering relevant information about precise requirements and preferences for cut resistant clothing.
Based on this information, extensive market research and working together with the multi-award-winning Department of Apparel from one UK’s leading Universities, CutPRO® is now offering the ultimate garment designs, taking 'durability' and 'quality' to a completely different level.
All garments are manufactured in the E.U. and are fully CE marked and certified (Cat II PPE). This means they fully comply with European laws, rules and regulations.
All garments have also been successful assessed against the updated and latest EN 388:2016 standard, confirming the following performance levels: Cut Resistance Level E (Level 5 on previous standard). Puncture Resistance Level 4. Tear Resistance Level 4. Abrasion Resistance Level 3.
If you are planning to attend the ‘Glass Focus 2019’ go and say hi to their team. You will be welcomed with open arms and an immense level of technical knowledge.
Robert Kaiser has also recently announced his company’s participation at next year’s glasstec2020 Expo in Dusseldorf, Germany:
"We have decided to present and exhibit our truly outstanding cut resistant clothing range at glasstec2020, the world’s largest and most respected Exhibition within the glass industry."
"There is no better platform for us to showcase our range of potentially lifesaving cut resistant garments to the world."
In case you have any questions in reference to cut resistant clothing, please email info@cut-pro.com or visit www.cut-pro.com.
END
About CutPRO®
CutPRO® Cut Resistant Clothing is a pioneering brand of highly protective clothing. Made from the world’s most reliable, fully certified and thoroughly field-tested cut resistant fabric Cut-Tex® PRO. The company’s social media presence: Facebook, LinkedIn, Twitter and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005029/en/
Contact information
Ryan Vickers, CDO
PPSS Group / CutPRO®
info@ppss-group.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom